Literature DB >> 15005256

Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.

Keita Uchino1, Hidekazu Sameshima, Toshihiro Miyamoto, Tadafumi Iino, Koji Kato, Hideho Henzan, Ken-ichi Aoki, Koji Nagafuji, Hisashi Gondo, Mine Harada.   

Abstract

We report a 72-year-old man with Waldenström's macroglobulinemia (WM) in whom diffuse large B-cell lymphoma (DLCL) occurred 17 years after the diagnosis of WM. The malignant cells of both DLCL and WM expressed CD20 on their surface. CHOP plus anti-CD20 monoclonal antibody, rituximab, were effective for both diseases, and the patient remains disease-free 17 months later.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15005256     DOI： 10.2169/internalmedicine.43.131

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


  3 in total

Review 1.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

2.  Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms.

Authors:  Masayuki Shiseki; Akihiro Masuda; Norimichi Watanabe; Masami Fujii; Tomofumi Kimura; Kentaro Yoshinaga; Naoki Mori; Masanao Teramura; Toshiko Motoji
Journal:  Hematol Rep       Date:  2011-08-30

3.  Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report.

Authors:  Wen-Ye Huang; Zhi-Yun Weng
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.